HER2 amplification also has been recognized as a rare resistant mechanism in lung adenocarcinoma occurring in 1–2% of total cases in patients and tends to be up to 13% in NSCLC patients with resistance to EGFR-TKIs [176,177,178,179]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.